Showing posts with label Prep. Show all posts
Showing posts with label Prep. Show all posts

March 9, 2019

PREP Use Among Men in Risk for HIV is Up 35% But Still Too Low




                                                   


By Tim Fitzsimons
Thirty-five percent of gay and bisexual men at high risk of HIV infection were using PrEP, or pre-exposure prophylaxis, the daily pill that prevents HIV infection, in 2017, according to data released Thursday by the Centers for Disease Control and Prevention. In 2014, just 6 percent of these men used PrEP.
However, despite the nearly 500 percent jump in PrEP use among men who have sex with men, the CDC notes “PrEP use remains too low, especially among gay and bisexual men of color.”
The study was presented Thursday in Seattle at the 2019 Conference on Retroviruses and Opportunistic Infections, a major annual HIV/AIDS conference, and was based on more than 8,000 interviews in 20 American cities. 
The data showed varying use among racial and ethnic groups. More than 40 percent of white gay and bisexual men at high risk of HIV used PrEP in 2017, while only 30 percent of their Latino counterparts and 26 percent of their African-American counterparts did so. The updated data highlights the fact that minorities access PrEP at lower rates than whites, despite being at higher risk of HIV infection.
The data also found high awareness of PrEP, which is also known by its brand name, Truvada, among all gay and bi men: Eighty-six percent of African-Americans know about it, as do 87 percent of Latinos and 95 percent of whites.
“The study’s findings suggest that efforts to increase PrEP awareness and use among populations at risk is working, but it remains underutilized,” according to a press memo distributed by the CDC. The CDC notes that the federal government’s “Ending the HIV Epidemic: A Plan for America,” which aims to reduce new infections by 90 percent by 2030, will rely heavily on ramping up PrEP use. Many people struggle to access PrEP because of its high cost — roughly $2,000 per month list price — and complex insurance procedures.
“Of the estimated one million Americans at substantial risk for HIV and who could benefit from PrEP, fewer than 10 percent are actually using this medication,” the CDC noted, referring to low uptake overall among heterosexual and injection-drug-using populations that are also at high risk of HIV infection.
The CDC said it is funding government and private health organizations’ efforts to spread awareness of PrEP, and “developing new ways to connect gay and bisexual men of color and transgender people to PrEP."

November 21, 2018

Every Person in Danger of HIV Should Have Available The Prevention Pill }}Medical Panel Says


  It's Not a long-term vaccine but it will do the same job...keep you from HIV even if your partner has it!
 One PILL will Keep HIV Away, So Why Would You become HIV by not taking Pill???? YOunger guys are mostly taking it but people that should know better are not!
A Truvada pill. The drug, used to treat people with HIV, also helps prevent the virus from infecting healthy people

An influential panel of medical experts recommended for the first time Tuesday that physicians offer preventive medication to anyone at high risk of acquiring HIV.
The U.S. Preventive Services Task Force estimated that 1.2 million people are eligible for the daily drug regimen, which is very effective at preventing HIV infection, but only 78,360 took the medication in 2016. About 40,000 people were newly diagnosed with HIV that year.
John Epling, a member of the task force and a professor of community medicine at the Virginia Tech Carilion School of Medicine and the Carilion Clinic, said routine discussion of the medication has not permeated primary care. He said he suspects that some doctors are not having conversations with patients who should be considered high risk.
“It’s just one of those things that haven’t diffused all the way through primary care yet,” Epling said in an interview. “The more familiar territory is in using condoms and avoiding multiple sexual partners.” The task force’s draft recommendations are aimed at persuading more doctors to bring up the subject of preventive drugs with their patients, he said. [Is HIV prevention pill right for you? CDC outlines how to tell whether you should be on the medication]
Pre-exposure prophylaxis, known as PrEP, is a combination of two drugs — tenofovir disoproxil fumarate and emitricitabine — made by Gilead Sciences and marketed as Truvada. Taken daily in a single pill, the FDA-approved medication greatly reduces the chance of acquiring HIV, according to research cited by the task force. The Centers for Disease Control and Prevention says that PrEP cuts the risk of contracting HIV through sex by more than 90 percent and reduces the risk by more than 70 percent for intravenous drug users.
Side effects — mainly nausea and mild, reversible kidney problems — are minor, but patient adherence to the drug program varied between 30 percent and 100 percent in research considered by the task force, an independent panel of experts on preventive medicine. 
The drug also is very expensive, at nearly $1,676 for a 30-day supply, according to Gilead. Most insurance covers the drugs, but critics have cited out-of-pocket costs as perhaps the biggest obstacle to staying on the medication.
In a statement, a Gilead spokesman disagreed, adding that “the CDC estimates that less than one percent of people who are indicated for Truvada for PrEP have an unmet need for financial assistance . . . Beginning September 1 of this year, we increased our patient support programs by raising the annual co-pay assistance from $4,800 to $7,200 and doubling patient eligibility for the Medication Assistance Program from six months to 12 months.”
Growth in the use of PrEP has been rapid, according to a 2018 study led by epidemiologists at the Rollins School of Public Health at Emory Universityin Atlanta. Its use rose from 3.3 people per 100,000 population in 2012 to 36.7 people in 2017. 
But use of the medication is more than twice as frequent in the Northeast than it is in the South, the researchers found, even though a disproportionate number of new HIV diagnoses occur in Southern states.
The development of effective therapies and better prevention have changed HIV from a death sentence to a manageable disease that people can live with for decades. The CDC estimates that 1.1 million people in the United States are infected with HIV, including an estimated 15 percent who don’t know they have it, the task force reported.
According to the CDC, new HIV diagnoses are disproportionately concentrated among injection drug users and black and Latino men who have sex with other men.
The task force singled out four groups of people it considers to be at high risk for HIV:
* Men who have sex with other men and have a partner with HIV, a recent sexually transmitted infection or inconsistently use condoms; * Heterosexuals who have a partner with HIV, a recent sexually transmitted infection or inconsistent condom use with a partner whose HIV status is unknown and is at high risk for contracting the virus;
* Injection drug users who share needles or are at risk of acquiring HIV through sexual activity.
* Sex workers or people trafficked for sex.
As it did in 2013, the task force also recommended that all people ages 15 to 65 and all pregnant women be screened for HIV.
The proposed recommendations are open for public comment until Dec. 26.
 Washington Post

September 14, 2018

We Have A Chemical HIV Cure (PREP) For Not Getting The Virus Yet Only 4% of Gay and Bi Men Are Using It








The Williams Institute—Only 4% of sexually active gay and bisexual men in the U.S. use Truvada as pre-exposure prophylaxis ( PrEP ) and 25% of young sexually active gay and bisexual men have never been tested for HIV.

The Williams Institute at UCLA School of Law finds that only 4% of sexually active gay and bisexual men in the United States use Truvada as pre-exposure prophylaxis ( PrEP ), which the Centers for Disease Control and Prevention regards as a highly effective tool to prevent the transmission of HIV.

In addition, researchers found that most sexually active gay and bisexual men aged 18-25 are not tested for HIV annually, as recommended by the CDC, and 25% of young men have never been tested.

"Our findings suggest that health education efforts are not adequately reaching sizable groups of men at risk for HIV infection," said the study's principal investigator Ilan H. Meyer, Distinguished Senior Public Policy Scholar at the Williams Institute. "It is alarming that high-risk populations of men who are sexually active with same-sex partners are not being tested or taking advantage of treatment advances to prevent the spread of HIV."

This is the first study to report on estimates of HIV testing and use of PrEP among gay and bisexual men using a national probability sample in the United States. In the study, researchers examined gay and bisexual men in three age groups: young ( 18-25 ), middle ( 34-41 ) and older ( 52-59 ).

Key findings
PrEP Use 
Only 4% of sexually active gay/bisexual men of all age groups use PrEP.
Visiting an LGBT health clinic and searching online for LGBT resources were associated with greater likelihood of PrEP use.

Slightly more than half ( 52% ) of young sexually active gay and bisexual men were familiar with PrEP as HIV prevention, compared with 79% of men aged 34-41.
Bisexual and non-urban men were less familiar with PrEP compared with gay-identified and urban men.
Most ( 68% ) men who were familiar with PrEP as HIV prevention had a positive attitude toward PrEP use—despite the low level of usage.

HIV Testing 
One quarter ( 25% ) of young gay and bisexual men had never tested for HIV in their lives, compared to approximately 8% of the middle and older groups of men.
45% of young sexually active gay and bisexual men had tested for HIV at least annually, compared with 59% of men aged 34-41 and 36% of those aged 52-59.

Black gay/bisexual men were more likely than White men to meet recommendations for HIV testing, which may be due to recent efforts to target Black men for HIV testing.
Visiting an LGBT health clinic and being out as gay or bisexual to health care providers were associated with greater likelihood of HIV testing.

"The extremely low rate of PrEP use, while not surprising given barriers to access in various parts of the country, is disappointing," said lead author Phillip L. Hammack, Ph.D., Professor of Psychology at the University of California, Santa Cruz. "I worry especially about younger men who didn't grow up with the concerns of HIV that men of older generations did. The low rate of HIV testing probably reflects a degree of complacency and cultural amnesia about AIDS."

"In the early days of the AIDS epidemic, gay and bisexual men had to rely on LGBT community sources to receive information about HIV prevention," said Meyer. "Our findings suggest that contact with LGBT community resources—health clinics and online information—still serves an important role in HIV prevention."

Truvada is currently the only FDA-approved form of PrEP.

The report, "HIV Testing and Pre-Exposure Prophylaxis ( PrEP ) Use, Familiarity, and Attitudes among Gay and Bisexual Men in the United States: A National Probability Sample of Three Birth Cohorts" appears in PLOS ONE and is co-authored by Phillip L. Hammack, Ph.D., Professor of Psychology at the University of California, Santa Cruz, Ilan H. Meyer, Ph.D., Distinguished Senior Public Policy Scholar at the Williams Institute, Evan A. Krueger, MPH, Research Coordinator at the Williams Institute, Marguerita Lightfoot, Ph.D., Professor of Medicine at the University of California, San Francisco, and David M. Frost, Ph.D., Senior Lecturer at University College London.

Research reported in this article is part of the Generations Study, supported by the National Institute of Child Health and Human Development ( NICHD ) of the National Institutes of Health, under award number R01HD078526. 
The Williams Institute at UCLA School of Law, a think tank on sexual orientation and gender identity law and public policy, is dedicated to conducting rigorous, independent research with real-world relevance.
—From a press release

August 6, 2018

Instead of keeping it Like A Secret Let's Celebrate Gay Men Can Have Sex Without Fear

Have you heard of the anti-AIDS drug PrEP? Most straight people are unaware of it. In 2015, the World Health Organization said “the efficacy of oral PrEP has been shown in four randomized control trials and is high when the drug is used as directed.” 
PrEP (Pre-exposure Prophylaxis) is a drug that allows you to have as much sex as you want, without a condom, and remain HIV-negative. If you use it, you probably won’t catch HIV. POZ magazine says that it has “100 per cent efficacy for those who stick to the treatment.”
Doctors recommend everyone use condoms, because although PrEP is very effective as a protection against HIV, it does not guard against the transmission of other sexually transmitted diseases.
Recently, Patrick William Kelly — a gay academic from Northwestern University who is writing a “global history of AIDS” — sounded the alarm about PrEP. For many straight people, Kelly’s discussion of PrEP may be the first they have heard of this revolutionary drug. 
Kelly’s concern is that the popularity of PrEP will cause gay men to stop using condoms. He worries:
“An entire generation of gay men has no memory or interest in the devastation [AIDS] wrought. AIDS catalyzed a culture of sexual health that has begun to disintegrate before our eyes. What is there to be done to bring it back?…The nonchalant dismissal of the condom today flies in the face of the very culture of sexual health that gay men and lesbians constructed in the 1980s.”

Doctors still recommend that everyone use condoms because although PrEP is effective as protection against HIV, it does not guard against the transmission of other sexually transmitted diseases. (Shutterstock)

There is one sentiment that is missing from Kelly’s article. Why doesn’t he celebrate the fact that gay men — and everyone else — can now have sex without fear of death? PrEP makes sex safer for everyone. It is just one new tool in the “safe sex arsenal.” Why not be happy about the fact that PrEP will undoubtedly save many lives?

Not a lethal illness anymore

Some might ask — isn’t AIDS still a lethal illness? Not so much. 
The gold standard in HIV treatment” (highly active antiretroviral therapy or HAART) was first introduced at the 1996 Vancouver International AIDS Society (IAS) Conference. According to Dr. Julio Montaner, director of the British Columbia Centre for Excellence in HIV/AIDS, “this was a pivotal moment, when HIV infection became a chronic manageable condition.” 
In 2014, The Globe and Mail reported that worldwide deaths from AIDS were massively decreasing
“In 2013, 1.5 million people died from AIDS-related causes worldwide, compared with 2.4 million in 2005, a 35 per cent decrease.” 
This state of affairs seems particularly significant when one considers hysterical early predictions concerning the effects of the disease. In 1987, Oprah Winfrey stated confidently that “research studies now project that one in five — listen to me, hard to believe — one in five heterosexuals could be dead from AIDS at the end of the next three years.” 
This never happened.

In this 1989 photo, protesters lie on the street in front of the New York Stock Exchange in a demonstration against the high cost of the AIDS treatment drug AZT. The protest was organized by ACT UP, a gay rights activist group. (AP Photo/Tim Clary)

It’s absolutely true that AIDS affects different demographics, ethnicities and geographies differently, and that gay men are not the only population to be affected by it worldwide. But the improvement in the lives of HIV-positive people everywhere is only in part due to the tireless efforts of doctors, researchers and health-care workers. 
It is also due to the tireless efforts of gay men everywhere — many of whom became safe-sex activists during the last 35 years, distributing pamphlets, marching and just generally spreading the news. 
So why would a gay professor characterize PrEP as a bad thing? Why is he worried that gay men — en masse — will suddenly start practising unsafe sex?
Kelly is the victim of another kind of infection — the notion that gay men are criminals whose desires must be controlled. 
This criminalization of homosexuals goes back as far as the notion of sodomy. 

Viewing homosexuality as criminal

In the England of Henry VIII, the punishment for sodomy was deathIndia today is still struggling to legalize same-sex encounters. 
In 1972, gay liberation theorist Guy Hocquenghem flatly stated in his book Homosexual Desire: “Homosexuality is first of all a criminal category.” 
Hocquenghem went on to suggest that even though the late 19th century brought a tendency to view homosexuality through the more “tolerant” lens of illness, the human need to view homosexuality as criminal is persistent.
“Certainly as we shall see later, psychiatry tends to replace legal repression with the internalization of guilt. But the passage of sexual repression from the penal to the psychiatric stage has never actually brought about the disappearance of the penal aspect.” 
Both the sexuality of gay men and the sexuality of women are a threat to the primacy of patriarchal male heterosexual desire. Heterosexist culture believes this threat must be controlled. The LaBouchere Amendment in England (1885) was used to incarcerate Oscar Wilde for his homosexuality as a crime of “gross indecency.”
But Labouchere was an amendment to legislation designed to control female prostitution  — a law that angered many 19th-century trailblazing feminists. 
When AIDS appeared in the early 1980s, some heterosexuals saw it as primarily a gay disease (AIDS was first called GRID — gay-related immune deficiency). They worried that gay men might infect straight people, especially children. 
In his influential book of essays, Is The Rectum A Grave?, Leo Bersani suggests that when small-town Americans wanted to ban HIV-positive hemophiliac children in schools, what they actually feared was the spectre of “killer gay men” acting too much like women:
Women and gay men spread their legs with an unquenchable appetite for destruction. This is an image with extraordinary power; and if the good citizens of Arcadia, Florida could chase from their midst a very law-abiding family it is, I would suggest, because in looking at three hemophiliac children they may have seen — that is unconsciously represented — the infinitely more seductive and intolerable image of a grown man, legs high in the air, unable to refuse the suicidal ecstasy of being a woman. 

A doctor holds Truvada pills, shown to help prevent HIV infection. (AP Photo/Jeff Chiu)

AIDS was not the first thing to make straight people think gay men had to be controlled. It simply fit like a glove on a fear of homosexuality that was already culturally endemic. 
Our society seems addicted to the notion that homosexuality is something uncontrollable and potentially lethal. So when AIDS came along, as the long-time AIDS worker Simon Watney wrote, it was “effectively being used as a pretext throughout the West to justify calls for increased legislation and regulation of those who are considered to be socially unacceptable.”
The concern over gay male imagined libidinal insanity is a throwback to an old trope. Gay men don’t need to be controlled; at least not any more than anyone else. And if you think otherwise? Well, it’s based on prejudice. Not fact.
This page was published on Aug 1, 2018 on The Conversation by,


July 2, 2018

The Pill With The Capability to Stop HIV is Getting Priced Out of Reach

Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections. But the officials are hitting roadblocks — the drug's price tag, which has surged in recent years, and changes in insurance coverage that put a heftier financial burden on patients.
Since brand-name Truvada was approved for HIV prevention six years ago, its average wholesale price has increased by about 45 percent. Now, the drug — which rakes in billions of dollars in annual global revenue for its manufacturer, Gilead Sciences — carries a list price of close to $2,000 for a 30-day supply. 
Most insurers cover the pill, also known as pre-exposure prophylaxis, or PrEP. It has been shown to be more than 90 percent effective in HIV prevention when taken daily, according to the Centers for Disease Control and Prevention.
But patients can get stuck with out-of-pocket costs that make the medicine unaffordable.
"If there is an example of the dysfunction in the American pharmaceutical system, it is this case," says James Krellenstein, a member of the AIDS advocacy group ACT UP New York. "We have the most effective tool for ending the HIV epidemic, and one reason we're unable to scale up because it costs so [much] unnecessarily."
As policymakers and the health system debate how to control ever-climbing drug prices, experts say this case underscores how patients are left holding the bag.
Private health plans are making patients responsible for a larger share of drug costs. And more are restricting the use of the "copay coupons" pharmaceutical companies have used to shield patients from out-of-pocket expenses. Insurers say the drug companies use coupons to steer consumers toward pricier meds. One way health plans are limiting their use is by no longer allowing them to count toward patients' deductibles. "This is one more thing that is going to push people off their medications," says Jim Pickett, a senior director at the AIDS Foundation of Chicago.
Jared Wile, who lives in Chicago, started taking PrEP about three years ago when he was dating someone with HIV. Wile, who has a $2,750 deductible, used a coupon to obtain the drug. He never paid anything out-of-pocket, he says.
Gilead waives up to $4,800 in out-of-pocket expenses for commercially insured patients.
That changed for Wile this past May when he learned the coupon no longer counted toward his deductible and that he would have to pay the full cost of the prescription — $1,600 per month — until he hit his deductible. Wile says he felt "blindsided" and stopped taking the medication.
Gilead spokesman Ryan McKeel says the company has made extra efforts to help patients overcome financial barriers. He cites assistance programs for uninsured and underinsured people.
"We have designed our assistance programs with the intent that people can benefit from their full value, and we cannot control the actions or decisions of health insurers," McKeel said via email.
The federal Centers for Disease Control and Prevention estimates that more than 1 million people are at high risk of contracting HIV, but Gilead says only about 167,000 people currently take PrEP.
Beyond the money crunch
Price is one of many barriers — alongside patients' lack of awareness and doctors' hesitation to prescribe — that threaten to exacerbate the already stark disparities in PrEP use and HIV infection rates.
One major disparity is along geographic lines. The South, for example, accounts for over half of new HIV diagnoses but only about 30 percent of new PrEP users, according to data from AIDSVu, which maps HIV disease and PrEP use. HIV rates and PrEP use also vary by race and ethnicity.
"We are not necessarily seeing that those most at risk are the ones starting PrEP," says Kristin Keglovitz Baker, the chief operating officer of Howard Brown Health, a Chicago health center.
Gilead has recently gone all-in with advertising to reach people at risk, including print campaigns and TV ads that will air through the summer. Since 2012, it has spent $28 million to fund U.S. organizations that seek to raise awareness of HIV, says McKeel, the company spokesman.
"We recognize that many people who are at high risk for HIV infection still face challenges in accessing Truvada for PrEP, and we are in regular dialogue with public health officials, advocates and physicians to better understand and, where possible, help to address these challenges," he added.
But price is also an impediment for publicly funded programs, which have limited budgets and are now shelling out more cash for the prevention effort.
"If it was only pennies ... we would be throwing it around," says Joey Mattingly, an assistant professor at the University of Maryland School of Pharmacy. "Because of how costly it is, we have to control it."
Some states — California and Florida among them — have launched PrEP assistance programs that can help patients cover the cost of the medication, along with required lab work and medical visits.
Beyond these state-based programs, some public health departments and HIV service organizations are hiring PrEP navigators to help patients traverse the maze of copays and deductibles and to improve recruitment and retention of new PrEP users.
Washington, D.C.'s health department has doubled down on prevention, and Truvada is key in that effort, says Michael Kharfen, the department's senior deputy director for HIV/AIDS, Hepatitis, STD and TB Administration.
Insurance usually covers PrEP, and patient assistance programs should fill any financial gaps, he says. But when that isn't feasible, the department steps in, distributing free Truvada starter packs to at-risk patients.
Kharfen says the city has in the past three years spent almost a million dollars just on Truvada pills, which it purchases at a discounted rate through the federal 340B program, which benefits certain health care providers that treat low-income people. And because of new publicity efforts, he expects the department will need to buy and distribute more pills — posing a conundrum.
Treating more people is net positive, he says. But "how do we sustain this?"
Medicaid programs generally cover PrEP, so they confront a similar situation. Outreach efforts lead to more beneficiaries who take the drug, but that, in turn, could subject the states' Medicaid budgets to financial hardship.
States are spending millions of dollars on the drug. California's Medicaid program, for example, spent about $50 million in 2017 and expects the costs to continue climbing. But officials said the expense is offset by long-term savings in preventing new HIV cases.
Massachusetts' Medicaid program spent about $22 million on Truvada that same year — about $18,000 per beneficiary, according to a spokeswoman for the agency's Executive Office of Health and Human Services. Those figures don't account for rebates the state receives from Gilead, which are undisclosed and considered proprietary information.
A complex solution and no competition
PrEP is only one part of HIV prevention, so help to pay for the pill is only one piece of the puzzle.
Patients also need regular HIV testing and medical care, which add to the cost borne both by patients and the health system. Some experts warn that Truvada's high price point could financially undermine such broad prevention efforts.
Competition could help.  
A generic version of the drug, manufactured by Teva Pharmaceuticals, is available abroad and gained approval for use last year from the federal Food and Drug Administration. When it becomes available in the United States, it could bring down prices, though it's unclear when that will happen. Gilead's own forecasts reflect that expectation, showing declines in future revenue from Truvada.
"When generics enter, brands lose market share," says David Howard, a health economist and professor at Emory University, who previously worked in the pharmaceutical industry.
For now, though, Truvada is the only PrEP option available in the U.S., he says. "From a company standpoint ... their best strategy is to make as much money as they can."
Kaiser Health News, a nonprofit news service covering health issues, is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN's coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation.

June 2, 2018

Enough People Are Taking PrEp to Lower HIV Infection Rates Around The World





Six years after the Food and Drug Administration approved a revolutionary HIV prevention pill known as PrEP, public health officials in select US cities have finally begun to conclude that it is likely taking a bite out of local HIV infection rates.
PrEP, short for pre-exposure prophylaxis, is akin to a birth control pill—only one that prevents HIV instead of pregnancy. The powder-blue tablet, which goes by the brand name Truvada, contains a pair of antiretroviral medications that were first approved to treat HIV in 2004. Truvada works by blocking HIV from replicating in the immune cells the virus infects—and, when used daily as PrEP—from establishing a permanent infection if someone is exposed to the virus. In other words, PrEP harnesses the power of a medication designed to control the virus in people living with HIV to prevent those without the virus from contracting it in the first place. Haven’t heard of PrEP? You like will soon thank its first-ever television ad campaign that will debut this month from Truvada’s manufacturer, Gilead Sciences. 
When HIV-negative men take Truvada daily, they lower their risk of contracting the virus through sex with men by an estimated 99% or more. This fact holds considerable promise considering that gay and bisexual men made up about 70% of the estimated 38,500 new HIV cases in the United States in 2015—the most recent year for which such a figure from the Centers for Disease Control and Prevention is available. Owing to a less robust pool of related data regarding vaginal intercourse, scientists have a foggier picture of how well Truvada prevents HIV transmission through this route; still, studies indicate that PrEP is at least 90% effective among women. PrEP, which has a wholesale cost of over $1,000 per month, is generally covered by insurance, including Medicaid. Gilead Sciences will cover up to $4,800 per year in out-of-pocket expenses related to filling the prescription. Many people—at least for now—pay nothing for their pill bottles 
Daily Antiretroviral Pill Found To Protect Healthy From AIDS Transmission




The drug’s game-changing potential notwithstanding, PrEP got off to a surprisingly inauspicious start. Probably only about 10,000 people tried PrEP during the first year or so after its approval in July 2012. Then, in late 2013, a slew of media reports began to question why so few people were taking PrEP. By early 2014, PrEP’s use began to pick up—and then soar. According to Gilead, an estimated 167,000 were on PrEP in the US as of early 2018. That’s up from 153,000 during the last quarter of 2017 and 125,000 during the first quarter of that year. Meanwhile, across the globe, an estimated 300,000 people are now using PrEP—and the medication has recently been approved for use by teenagers.
Study after study has found consistent demographic patterns in the US behind these figures: In short, PrEP users are predominantly white, gay and bisexual men over 25. (A modest proportion of users are women, although this population isn’t expanding too rapidly.)
What such data reveals, sadly is that among gay and bi men, the folks who would most benefit from PrEP are actually those using it the least—gay and bi African Americans, who account for one in four new infections in the United States. Indeed, researchers have found that perhaps no more than 10% of PrEP users are black. What’s more, Latino gay and bi men—whose increasing HIV rate has alarmed and perplexed public health experts—apparently use PrEP only a bit more common than their African-American counterparts. 
STD advertising on the subway in New York
Advertising on the subway in New York on Sunday, January 3, 2016 promotes the use of HIV testing, prophylactic drugs and condoms to combat the spread of AIDS and sexually transmitted infections. (Photo by Richard Levine/Corbis via Getty Images)
  all STI rate in their communities. 




PrEP’s introduction has certainly raised various concernsmost notably regarding the question of whether Truvada will accelerate the long-declining rate of condom usage among gay and bi men. A recent review of numerous PrEP studies conducted from 2014 to 2017 found that starting Truvada for HIV prevention was associated in an uptick in sexually transmitted infection (STI) diagnoses, which suggests that men were indeed forgoing condoms more often during the period immediately following going on PrEP. That said, a CDC modeling study recently projected that even if these men’s condom adherence plummets, their use of PrEP may actually help lower the overall STI rate in their communities. That’s because PrEP users typically undergo STI screening every three to six months—which can identify and treat infections promptly.
On the side-effect front, PrEP often gets a bad rap. One study found its safety, at least in the short-to-medium term, was favorable to aspirin. Truvada is associated with small, initial reductions in bone mineral density and kidney function. However, studies have indicated that both shifts are reversible after individuals stop taking PrEP, and there have been no reports of Truvada leading to an actual bone fracture or kidney disease among HIV-negative individuals using it for prevention. How do we know if PrEP is driving down HIV?
The strongest evidence to date that PrEP works on a grand scale come from a recent Australian study. Starting in early 2016, researchers in New South Wales provided PrEP to an enthusiastic surge of 7,600 gay and bi men living in the state. After its first year, the study saw an astonishing 32% decline in diagnoses of recently contracted HIV among all gay and bi men in New South Wales.
This demographic’s HIV diagnosis rate had been stable during the preceding years—a fact that contributed to the study authors’ conclusion that PrEP was the key variable propelling this plunge in HIV transmissions.
As for the US HIV epidemic, local governments in New York City, San Francisco, and Seattle have been particularly proactive in promoting PrEP (and collecting data about its use), and now seem to be reaping the benefits.
In New York City, there was a nearly 15% drop between 2015 and 2016 in new HIV diagnoses among gay and bi men, to just over 1,200 cases—the steepest one-year drop on record.
“The only major change we saw [during this period] was explosive increases in the uptake of PrEP” among gay and bi men, said Demetre Daskalakis, deputy commissioner of the city’s Division of Disease Control. “With some of our data indicating that nearly 30% of these men currently use PrEP. It seems clear from our data and the reports from other jurisdictions that PrEP is an effective strategy to eliminate new HIV transmissions and could be a scalable public health intervention.”
In other words, PrEP works and is certainly poised to benefit other populations at high risk for HIV in cities across the country.
San Francisco’s overall HIV diagnosis rate has been on a freefall in recent years—dropping from 532 in 2007 to 223 in 2016, including a 50% reduction after 2012. Susan Buchbinder, a leader of the HIV team at the San Francisco Department of Public Health, said that “PrEP is likely helping to drive down new infections” in the Bay Area city. An estimated 20,000 people take Truvada for prevention there—representing perhaps half of those residents who are at significant risk of HIV.
The HIV diagnosis rate in King County, which includes Seattle, has charted its own healthy HIV decline of late, with local public health officials also coming to the conclusion that the local popularity of PrEP is apparently contributing to this shift.
All these data strongly suggest that there’s a sea change benefitting white gay and bi men in particular who live in those major urban areas where PrEP has woven its way into the fabric of gay sex. For them, HIV transmission is becoming increasingly uncommon, and may soon collapse.
Meanwhile, their black and Latino counterparts, especially those in the US South—the new hotbed of the US epidemic, where PrEP happens to lag behind other regions—are essentially being left behind.

Featured Posts

A Mob of 10 Men Attacks a Gay Man in Arizona

Police are investigating, though they aren't calling the attack as a hate crime. BY  MATHEW RODRIGUEZ Ou...